Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
PTP22 CRISPR/Cas9 KO Plasmid (h): sc-416917
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- PTP22 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the PTP22 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: PTP22 Antibody (E-5): sc-393766
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PTP22 CRISPR/Cas9 KO Plasmid (h) | sc-416917 | 20 µg | $397.00 |
Overview
PTPN22 encodes the cytosolic protein tyrosine phosphatase PTP22 (also known as LYP), a key negative regulator of antigen receptor signaling in immune cells. By dephosphorylating signaling intermediates downstream of the T cell receptor and related pathways, PTP22 modulates thresholds for lymphocyte activation, cytokine production, and immune tolerance. Genetic variation and altered activity of PTPN22 are strongly associated with susceptibility to multiple autoimmune and inflammatory conditions, making it a widely studied node in immunoreceptor signaling networks. Functional studies often link PTP22 to pathways controlling proximal kinase/phosphatase balance, NFAT/NF-κB-dependent transcriptional programs, and immune cell differentiation.
PTP22 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the PTPN22 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the PTPN22 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the PTPN22 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish PTP22 protein expression.
This CRISPR knockout system enables efficient generation of PTPN22-deficient cell models for investigation of PTP22 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting PTPN22 exon(s) critical for PTP22 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple PTPN22 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by PTP22 CRISPR/Cas9 KO Plasmid (h) and PTP22 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the PTPN22 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by PTP22 HDR Plasmid (h) and PTP22 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by PTPN22 homology arms to support homology-directed repair at defined PTPN22 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.